Kurma Partners Achieves First Close of New EUR 250 Million Biofund IV
Thursday, 3 October 2024, 00:06
Kurma Partners has successfully achieved the first close of its new EUR 250 million Biofund IV. This landmark milestone highlights the commitment to invest in groundbreaking biotech innovations. With an initial closing of EUR 140 million, the fund will target 16 to 20 new investments that follow Kurma's established investment strategy.
Investment Focus Areas
- Biotech Advancements
- Pharmaceutical Innovations
- Healthcare Technologies
Looking Ahead
The raised capital demonstrates robust interest in the biotech sector, paving the way for significant research breakthroughs and advancements in medicine.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.